Put Warnings About Liver Damage With Hep C Meds Into Perspective

April 2017

You'll hear about a link between hepatitis C meds and liver damage...especially in patients who also have hepatitis B.

FDA now requires a boxed warning about the risk of hepatitis B reactivation with newer hep C meds...Epclusa, Harvoni, Zepatier, etc.

And a recent report from Institute for Safe Medication Practices warns about rare cases of liver injury and failure tied to these meds. Viekira Pak and Technivie already have warnings in their labeling about liver injury, mostly in patients with advanced liver disease.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter membership benefits include:

12 issues every year — what you need to know and do, right now
Quick, practical reference charts and tools
Comprehensive CE library to meet license renewal and state requirements
Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
Plus much more!

Choose the right tier for your needs today.

Already a subscriber? Log in

Volume pricing available. Get a quote